INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Capricor Therapeutics, Inc. (CAPR) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

A class action lawsuit has been filed against Capricor Therapeutics for allegedly making false statements regarding changes to its statistical analysis plan for the Deramiocel drug candidate without FDA approval. The FDA's briefing documents revealed concerns about the integrity of the clinical data analysis, leading to a 64% stock price decline on July 27, 2026, followed by a 36% decline after an advisory committee voted against the drug's efficacy on July 29, 2026.